Stifel Financial Corp Has $18.31 Million Stock Position in Harrow, Inc. (NASDAQ:HROW)

Stifel Financial Corp cut its stake in shares of Harrow, Inc. (NASDAQ:HROW - Free Report) by 25.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 407,264 shares of the company's stock after selling 135,583 shares during the quarter. Stifel Financial Corp owned 1.15% of Harrow worth $18,311,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in HROW. First Turn Management LLC bought a new stake in Harrow during the 3rd quarter worth approximately $14,683,000. Private Capital Management LLC grew its stake in shares of Harrow by 7.8% in the first quarter. Private Capital Management LLC now owns 3,012,393 shares of the company's stock worth $39,854,000 after purchasing an additional 217,896 shares during the last quarter. Assenagon Asset Management S.A. acquired a new stake in Harrow in the third quarter valued at $8,572,000. Charles Schwab Investment Management Inc. raised its position in Harrow by 195.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company's stock worth $11,313,000 after purchasing an additional 166,602 shares during the last quarter. Finally, Braidwell LP raised its position in Harrow by 47.9% during the 3rd quarter. Braidwell LP now owns 439,638 shares of the company's stock worth $19,766,000 after purchasing an additional 142,450 shares during the last quarter. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Lake Street Capital increased their price target on Harrow from $45.00 to $55.00 and gave the company a "buy" rating in a research note on Friday, October 4th. B. Riley decreased their target price on shares of Harrow from $73.00 to $69.00 and set a "buy" rating for the company in a research report on Wednesday, December 4th. Finally, Craig Hallum boosted their price target on shares of Harrow from $45.00 to $65.00 and gave the stock a "buy" rating in a research report on Friday, October 4th.

Harrow Trading Down 5.5 %

Shares of NASDAQ:HROW traded down $2.18 during midday trading on Tuesday, reaching $37.77. The company's stock had a trading volume of 248,839 shares, compared to its average volume of 507,097. Harrow, Inc. has a fifty-two week low of $9.13 and a fifty-two week high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm has a 50 day moving average price of $46.99 and a two-hundred day moving average price of $35.65. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of -42.50 and a beta of 0.69.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.